On October 17, 2018 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, presented the results from its ongoing study utilizing Cchek, its artificial intelligence (AI) driven early cancer detection technology, at the 30th Anniversary AACR (Free AACR Whitepaper) Special Conference – Convergence: Artificial Intelligence, Big Data and Prediction in Cancer (Press release, Anixa Biosciences, OCT 17, 2018, View Source [SID1234530497]). This AACR (Free AACR Whitepaper) special conference covered the state of research in understanding cancer from incident to early diagnosis, prevention, and treatment using big data and machine learning. The meeting was held October 14–17, 2018 in Newport, Rhode Island and was attended by global leaders in the intersection of cancer research and artificial intelligence.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Anixa, for the first time, presented data demonstrating the ability of Cchek to distinguish, among patients scheduled for biopsy, those who have high risk prostate cancer and those who have benign conditions or low grade cancer, for whom surgery is not required and a biopsy is unnecessary. In addition, Anixa’s Cchek data showed the ability to distinguish healthy males from high risk prostate cancer patients with a sensitivity of 89% and a specificity of 100%. This study further demonstrated the potential for Cchek to reduce the number of unnecessary prostate biopsies by up to 56%, while still retaining 89% sensitivity for detecting prostate cancers.
Dr. Amit Kumar, Anixa President and CEO stated, "We are pleased with the results of our ongoing study presented at the AACR (Free AACR Whitepaper) AI conference, and we are excited about the potential for us to dramatically reduce the number of unnecessary prostate biopsies. The ability to distinguish between high risk prostate cancer patients and those with a benign condition or low grade, non-surgically treated cancer is significant, and is a distinct differentiator between Cchek and many other liquid biopsy tests being developed today."